A Preliminary Study on the Impact of Detrusor Overactivity on the Efficacy of Selective Bladder Denervation for the Treatment of Female Refractory Overactive Bladder

  • Raphaëlle Brière
    Faculty of Medicine, Université Laval, Québec, Québec, Canada
    Search for articles by this author
  • Eboo Versi
    Department of Obstetrics, Gynecology, Reproductive Sciences, Rutgers, New Brunswick, NJ
    Search for articles by this author
  • Patrick O. Richard
    Division of Urology, Department of Surgery, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, Québec, Canada
    Search for articles by this author
  • Matthieu Gratton
    Division of Urology, Department of Surgery, Faculty of Medicine, CHU de Québec-Université Laval, Québec, Québec, Canada
    Search for articles by this author
  • Le Mai Tu
    Address correspondence to: Le Mai Tu, M.D., F.R.C.S.C., M.Sc., Division of Urology, Departments of Surgery, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, 3001, 12ieme avenue N, Sherbrooke, Québec J1H 5N4, Canada.
    Division of Urology, Department of Surgery, Faculty of Medicine and Health Sciences, Centre Hospitalier Universitaire de Sherbrooke and Centre de Recherche du CHUS, Sherbrooke, Québec, Canada
    Search for articles by this author
Published:November 30, 2019DOI:



      To determine whether the presence of detrusor overactivity (DO) is associated with the 12-week and 12-month clinical outcomes of selective bladder denervation (SBD) in women with refractory overactive bladder (OAB).


      Prospective single institutional study of refractory OAB females who underwent a urodynamic study and were categorized according to DO status (DO− vs DO+) prior to receiving SBD.


      Among the 23 patients, 10 were DO− and 13 were DO+. Both groups reported improvement at 12 weeks on the 24-hour pad weight test, in urgency urinary incontinence (UUI) and urgency. At 12 months, both groups still reported improvement in urgency, but only the DO− group reported reduction on the pad weight test and only the DO+ group maintained improvement in the UUI rate. Clinical success (≥50% reduction in UUI) was achieved by all DO− and by 69% of DO+ patients at 12 weeks, and by 60% of DO− and 92% of DO+ patients at 12 months. Treatment benefit (Treatment Benefit Scale ≤2) was reported in 90% of DO− and 85% of DO+ patients at 12 weeks, and in 60% of DO− and 85% of DO+ patients at 12 months. When directly comparing both group outcomes, the only significant difference was the greater reduction of UUI in the DO− group at 12 weeks (−9.0 vs −6.5; P = .045).


      Refractory OAB females appear to be effectively treated by SBD regardless of baseline DO status. DO status does not seem to be associated with the 12-week and 12-month outcomes of SBD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Haylen BT
        • de Ridder D
        • Freeman RM
        • et al.
        An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
        Neurourol Urodyn. 2010; 29: 4-20
        • Stewart WF
        • Van Rooyen JB
        • Cundiff GW
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20: 327-336
      1. 6 International Consultation on Incontinence. 6th Report. Tokyo September 2016. Committee I, p.49-61; Committee IV, P. 365-370.

        • Corcos J
        • Przydacz M
        • Campeau L
        • et al.
        CUA guideline on adult overactive bladder.
        Can Urol Assoc J. 2017; 11: E142-E173
        • Purves JT
        • Spruill L
        • Rovner E
        • et al.
        A three dimensional nerve map of human bladder trigone.
        Neurourol Urodyn. 2017; 36: 1015-1019
        • Andersson KE
        Bladder activation: afferent mechanisms.
        Urology. 2002; 59: 43-50
        • Tu LM
        • De Wachter S
        • Robert M
        • et al.
        Initial clinical experience with selective bladder denervation for refractory overactive bladder.
        Neurourol Urodyn. 2019; 38: 644-652
        • De Wachter S
        • Benson KD
        • Dmochowski RR
        • et al.
        Six-month results of selective bladder denervation in Women with refractory overactive bladder.
        J Urol. 2019; 201: 573-580
        • Malone-Lee J
        • Henshaw DJ
        • Cummings K
        Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response.
        BJU Int. 2003; 92: 415-417
        • Gormley EA
        • Lightner DJ
        • Faraday M
        • et al.
        Association AU, Society of Urodynamics FmPM. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment.
        J Urol. 2015; 193: 1572-1580
      2. Cystoscopic ablation Via RF Energy Clinical Trial (CARET2). Accessed August 1st, 2018.

        • Notte SM
        • Marshall TS
        • Lee M
        • et al.
        Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder.
        BMC Urol. 2012; 12: 26
        • Coyne KS
        • Thompson CL
        • Lai JS
        • et al.
        An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.
        Neurourol Urodyn. 2015; 34: 255-263
        • Rosier PFWM
        • Schaefer W
        • Lose G
        • et al.
        International continence society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study.
        Neurourol Urodyn. 2017; 36: 1243-1260
        • Colman S
        • Chapple C
        • Nitti V
        • et al.
        Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder.
        Urology. 2008; 72: 803-807
        • Westney OL
        • Lee JT
        • McGuire EJ
        • et al.
        Long-term results of Ingelman-Sundberg denervation procedure for urge incontinence refractory to medical therapy.
        J Urol. 2002; 168: 1044-1047
        • Fugett J
        • Phillips L
        • Tobin E
        • et al.
        Selective bladder denervation for overactive bladder (OAB) syndrome: from concept to healing outcomes using the ovine model.
        Neurourol Urodyn. 2018; 37: 2097-2105
        • Ingelman-Sundberg A
        Partial denervation of the bladder, a new operation for the treatment of urge incontinence and similar conditions in women.
        Acta Obstet Gynecol Scand. 1959; 38: 487-502
        • Coyne KS
        • Payne C
        • Bhattacharyya SK
        • et al.
        The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey.
        Value Health. 2004; 7: 455-463
        • Nitti VW
        • Rovner ES
        • Bavendam T
        Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
        BJU Int. 2010; 105: 1268-1275
        • Rachaneni S
        • Latthe P
        Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
        Int Urogynecol J. 2017; 28: 805-816
        • Peyronnet B
        • Mironska E
        • Chapple C
        • et al.
        A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment.
        Eur Urol. 2019; 75: 988-1000
        • Roosen A
        • Chapple CR
        • Dmochowski RR
        • et al.
        A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature.
        Eur Urol. 2009; 56: 810-819
        • Hanna-Mitchell AT
        • Kashyap M
        • Chan WV
        • et al.
        Pathophysiology of idiopathic overactive bladder and the success of treatment: a systematic review from ICI-RS 2013.
        Neurourol Urodyn. 2014; 33: 611-617
        • Andersson KE
        Detrusor myocyte activity and afferent signaling.
        Neurourol Urodyn. 2010; 29: 97-106
        • Drake MJ
        • Kanai A
        • Bijos DA
        • et al.
        The potential role of unregulated autonomous bladder micromotions in urinary storage and voiding dysfunction; overactive bladder and detrusor underactivity.
        BJU Int. 2017; 119: 22-29
        • Heppner TJ
        • Tykocki NR
        • Hill-Eubanks D
        • et al.
        Transient contractions of urinary bladder smooth muscle are drivers of afferent nerve activity during filling.
        J Gen Physiol. 2016; 147: 323-335
        • Birder L
        • Andersson KE
        Urothelial signaling.
        Physiol Rev. 2013; 93: 653-680
        • Homma Y
        • Kondo Y
        • Takahashi S
        • et al.
        Reproducibility of cystometry in overactive detrusor.
        Eur Urol. 2000; 38: 681-685